How big is Coya Therapeutics, Inc.?

As of Jun 18, Coya Therapeutics, Inc. has a market capitalization of 88.88 million, with net sales of 3.69 million and a net profit of -17.14 million over the last four quarters. The company reported shareholder's funds of 39.58 million and total assets of 44.35 million as of Dec 24.

Market Cap: As of Jun 18, Coya Therapeutics, Inc. has a market capitalization of 88.88 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Coya Therapeutics, Inc. reported net sales of 3.69 million and a net profit of -17.14 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 39.58 million and total assets of 44.35 million.

What does Coya Therapeutics, Inc. do?

Coya Therapeutics, Inc. is a micro-cap company in the miscellaneous industry, reporting net sales of $0 million and a net loss of $7 million as of March 2025, with a market cap of $88.88 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -51.35%.

Overview:<BR>Coya Therapeutics, Inc. operates in the miscellaneous industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -7 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 88.88 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.06 <BR>Return on Equity: -51.35% <BR>Price to Book: 2.66<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold Coya Therapeutics, Inc.?

Is Coya Therapeutics, Inc. overvalued or undervalued?

As of August 12, 2025, Coya Therapeutics, Inc. is considered overvalued with a valuation grade of "does not qualify," reflected by a Price to Book Value of 2.94, a negative ROE of -51.35%, and poor stock performance compared to the S&P 500, returning -5.28% against the index's 17.14%.

As of 12 August 2025, the valuation grade for Coya Therapeutics, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 2.94 and an EV to Sales ratio of 17.02, which suggest a high valuation relative to its financial performance. Additionally, the negative ROE of -51.35% further underscores the company's struggles.<BR><BR>In comparison to its peers, Coya Therapeutics, Inc. has a notably worse EV to EBITDA ratio of -3.23, while Gaia, Inc. has a much higher ratio of 10.4728, indicating a more favorable valuation in that regard. Similarly, Research Solutions, Inc. shows a significantly negative EV to EBITDA of 30.0380, reinforcing the challenges faced by Coya. Over the past year, Coya's stock has underperformed relative to the S&P 500, returning -5.28% compared to the index's 17.14%, which further supports the view that the stock is overvalued in its current state.

Is Coya Therapeutics, Inc. technically bullish or bearish?

As of August 28, 2025, Coya Therapeutics, Inc. shows a mildly bullish technical trend despite mixed signals across time frames and underperformance compared to the S&P 500, warranting caution.

As of 28 August 2025, the technical trend for Coya Therapeutics, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The daily moving averages are mildly bullish, supporting the overall positive shift. However, the weekly KST and OBV are bearish, and the Bollinger Bands show a sideways trend on the weekly and bearish on the monthly. Dow Theory presents a mildly bearish stance weekly but mildly bullish monthly.<BR><BR>In terms of performance, Coya has underperformed the S&P 500 across all observed periods, with a year-to-date return of 0.17% compared to the S&P 500's 12.22%, and a one-year return of -5.28% against 17.14%. Overall, the current technical stance is mildly bullish, but caution is warranted due to mixed indicators and underperformance relative to the benchmark.